Cargando…
Increased autophagy in EOC re-ascites cells can inhibit cell death and promote drug resistance
As the major and preferred treatment for ovarian cancer ascites, chemotherapy can reduce or inhibit recurrent ascites (hereafter re-ascites); however, some patients still experience re-ascites. Therefore, this study investigated cases in which epithelial ovarian cancer (EOC) patients experienced re-...
Autores principales: | Liu, Yu, Tang, Jing, Liu, Duanyang, Zhang, Lei, He, Yan, Li, Jing, Gao, Lei, Tang, Dai, Jin, Xiaoming, Kong, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856849/ https://www.ncbi.nlm.nih.gov/pubmed/29549251 http://dx.doi.org/10.1038/s41419-018-0449-5 |
Ejemplares similares
-
The impact of inflammatory cells in malignant ascites on small intestinal ICCs’ morphology and function
por: Li, Jing, et al.
Publicado: (2015) -
HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect
por: Liu, Duanyang, et al.
Publicado: (2018) -
Activation of SphK2 contributes to adipocyte-induced EOC cell proliferation
por: Dai, Lan, et al.
Publicado: (2022) -
Inhibition LC3B can increase chemosensitivity of ovarian cancer cells
por: Tang, Jing, et al.
Publicado: (2019) -
The proteomic comparison of peripheral circulation-derived exosomes from the epithelial ovarian carcinoma (EOC) patients and non-EOC subjects
por: Peng, Peng, et al.
Publicado: (2019)